NRC-AN-019

Catalog No. A13562

NRC-AN-019 is an orally administered tyrosine kinase inhibitor (TKI) of the Bcr-Abl protein-tyrosine kinase. NRC-AN-019 is more effective in inhibiting angiogenic potential and proliferation of both MDAMB231 and HTB20/BT474 cells.
Catalog Num A13562
M. Wt 517.431
Formula C25H17F6N5O
Purity >98%
Storage at -20 °C 3 years (powder form); at -20 °C 6 months (Solution base)
CAS No. 879507-25-2
Synonyms AN019, AN 019, NRC-an-019
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)NC3=NC=CC(=N3)C4=CN=CC=C4
NRC-AN-019 is an orally administered tyrosine kinase inhibitor (TKI) of the Bcr-Abl protein-tyrosine kinase. NRC-AN-019 is more effective in inhibiting angiogenic potential and proliferation of both MDAMB231 and HTB20/BT474 cells.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 19.33 mL 96.63 mL 193.26 mL
0.5 mM 3.87 mL 19.33 mL 38.65 mL
1 mM 1.93 mL 9.66 mL 19.33 mL
5 mM 0.39 mL 1.93 mL 3.87 mL

*The above data is based on the productmolecular weight 517.431. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.